Sanofi-Regeneron Dupixent data reinforce use in atopic dermatitis patients with skin of color Ruchika Sharma9 Jun 2025 1:12 PM ISTParis: Sanofi has announced that results from the DISCOVER phase 4, single-arm, open-label study assessing Dupixent (dupilumab) in adults and...
Sanofi launches 2025 Global Employee Stock Purchase Plan Ruchika Sharma8 Jun 2025 12:30 PM ISTParis: Sanofi's global employee shareholder plan, Action 2025, opens on June 10, 2025, to around 70,000 employees in 55 countries.In 2024 alone,...
Sanofi Rilzabrutinib gets USFDA orphan drug designation for sickle cell disease Ruchika Sharma4 Jun 2025 1:30 PM ISTParis: Sanofi has received orphan drug designation from the US Food and Drug Administration (FDA) for rilzabrutinib, a novel, advanced, oral,...
Sanofi to acquire Blueprint Medicines for up to USD 9.5 billion Ruchika Sharma3 Jun 2025 3:23 PM ISTParis: Sanofi and Blueprint Medicines Corporation, a US-based, publicly traded biopharmaceutical company specializing in systemic mastocytosis...
Itepekimab met primary endpoint in one of two COPD phase 3 studies: Sanofi, Regeneron Ruchika Sharma1 Jun 2025 3:00 PM ISTParis: Sanofi has announced that the AERIFY-1 phase 3 study evaluating itepekimab in former smokers with inadequately controlled chronic...
Sanofi broadens immunology pipeline with acquisition of DR-0201 Ruchika Sharma27 May 2025 11:00 AM ISTParis: Sanofi has completed the acquisition of DR-0201, a targeted bispecific myeloid cell engager, from Dren Bio, Inc., a private...
Sanofi to buy Vigil Neuroscience in USD 470 million deal Ruchika Sharma22 May 2025 12:33 PM ISTParis: Sanofi has announced that it has entered into an agreement to acquire Vigil Neuroscience, Inc., a publicly traded clinical-stage...
Sanofi sells controlling stake of consumer healthcare business Opella Ruchika Sharma2 May 2025 3:35 PM ISTParis: Sanofi has announced the closing of the sale to CD&R of a 50.0% controlling stake of its consumer healthcare business Opella. Sanofi...
Sanofi invests Euro 15 milion in Innate Pharma Ruchika Sharma25 April 2025 2:30 PM ISTMarseille: Innate Pharma SA has announced a €14,999,998.59 capital increase subscribed by Sanofi.As announced on April 23, 2025, and given the...
Sanofi, Regeneron Pharma secures USFDA approval for Dupixent for chronic spontaneous urticaria Ruchika Sharma19 April 2025 1:15 PM ISTParis: Sanofi and Regeneron Pharma have received approval from the US Food and Drug Administration (FDA) for Dupixent (dupilumab) for the...
USFDA grants orphan drug designation to Sanofi Rilzabrutinib for two rare diseases Ruchika Sharma3 April 2025 2:45 PM ISTParis: Sanofi has announced that the US Food and Drug Administration (FDA) has granted orphan drug designation to Rilzabrutinib, an...
Sanofi Dupixent approved in Japan for COPD Ruchika Sharma30 March 2025 10:00 AM ISTDupixent is intended for injection under the skin (subcutaneous injection) and is given every other week.
